PRINCETON, N.J., Jan. 31, 2013 /PRNewswire/ -- Novo Nordisk (NYSE: NVO), a global healthcare company with 90 years of innovation and leadership in diabetes care, announced the promotion of four corporate vice presidents to senior vice presidents. Effective March 1, 2013, the following members of the U.S. Executive Team will assume the title of senior vice president in their respective areas: Andy Ajello, U.S. National Diabetes Sales; Camille Lee, U.S. Diabetes Marketing; Alan Moses, MD, global chief medical officer; and Anne Phillips, MD, U.S. Clinical, Medical and Regulatory Affairs.
"The size and complexity of the U.S. business has increased dramatically, which places great demands on our leaders," said Jerzy Gruhn, president of Novo Nordisk Inc., the company's US affiliate. "Our global leaders have recognized that certain positions within the U.S. organization now have such high impact on the company's overall performance that they should be elevated to the senior vice president level. The same is true for the role of Global Chief Medical Officer, which has grown in impact with the increasing number of promising projects in our development pipeline."
Andy, Camille and Anne will continue to serve on the U.S. Executive Team, reporting to Jerzy. Alan will move to the company's global headquarters in Denmark and report to Mads Krogsgaard Thomsen, executive vice president and chief science officer, later in 2013. All will become members of the company's senior management board, a group comprised of Novo Nordisk's senior-most leaders.
Andy has been in the pharmaceutical industry for nearly 20 years. He joined Novo Nordisk in March 2001 and currently leads the National Diabetes Sales strategy and the company's approximately 3,200 person field sales organization. During his 12 years with the company, he has been widely recognized for developing and motivating a high-performing sales team. His responsibilities include oversight of the entire diabetes sales organization, including managed markets sales, field force operations, and strategic sales initiatives.
Camille has more than 25 years of experience in the industry. She joined Novo Nordisk in 1985 as a sales representative in Southern California, and through her tenure with the company has held national and international positions of increasing authority in the areas of marketing, strategic launch planning, and sales management. Over the past six years, she has built a strong diabetes marketing team of 365 people that has been recognized internally and externally for their best-in-class initiatives. She currently has oversight for the marketing of all in-line and future brands, as well as the organization's Diabetes Educator Program.
Alan joined Novo Nordisk in 2004 from Harvard Medical School and the Joslin Diabetes Center as associate vice president for clinical research and medical affairs – endocrinology, and in 2007 was named chief medical officer for North America. One year later, he was appointed to global chief medical officer. He is involved in the full spectrum of Novo Nordisk's diverse diabetes work from drug discovery to addressing the implications of diabetes for patients, healthcare professionals, and healthcare systems.
Anne brings more than 20 years of medical, research, and regulatory experience to her role. She currently leads an integrated drug development, medical, regulatory, and safety team of more than 550 people, and plays a key role in advancing Novo Nordisk's diabetes and biopharmaceutical clinical development pipelines. She is responsible for the efficient development and delivery of compounds in clinical trials, including product lifestyle and in-licensed compounds.
Full biographies of the Novo Nordisk leadership team may be found here.
Earlier today, Novo Nordisk released its 2012 earnings statement, highlighting 43 consecutive quarters of double digit growth. The U.S. now contributes more than 40% (42%) to the company's global revenues.
About Novo Nordisk Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com. For more information about our U.S. activities, follow us on Twitter at @NovoNordiskUS.
SOURCE Novo Nordisk